The epidemic prevention granules, which contain six traditional Chinese medicines, developed by Zhejiang Benefit Pharmaceutical Co Ltd have been sold to Italy, Spain, Serbia and other European countries since their launch. At present, revenue from the granules has passed 10 million yuan ($1.4 million).

The Lishui-based company was the first in Zhejiang province to study the use of Chinese medicine granules for epidemic prevention during the COVID-19 outbreak.

Doctor Li Wenlong, who has a temporary post in the company, uses his expertise to help it develop new products and open up new markets.

During the outbreak, Lishui coordinated with 111 talents with doctoral degrees, including Li, to provide technical guidance to more than 100 local enterprises. To date, they have helped the enterprises develop 56 new products, facilitated in-depth cooperation between the enterprises and 44 well-known universities and scientific research institutions.

Additionally, since the outbreak, Lishui has sent 2,196 cadres, who have professional backgrounds or rich experience, to 4,933 enterprises to help them resume work and production under the premise of epidemic prevention and control.